Online ISSN: 2149-3189
2015
Monthly
Nicaea Medical Publishing
Türkiye

The Relationship Between Metabolic Syndrome and Urogenital Health Markers: A Cross-Sectional Study

Feyza Sönmez Topcu, Gökhun Özmerdiven, Hüseyin Cihan Demirel
DOI
https://doi.org/10.18621/eurj.1780810
Abstract
Objectives: Metabolic syndrome (MetS) is a cluster of metabolic abnormalities that increases cardiovascular risk and may adversely affect urogenital function, particularly erectile and prostate-related parameters. To evaluate the association between MetS and urogenital health markers, including erectile function, lower urinary tract symptoms, prostate volume, and internal iliac artery resistive index (RI).
Methods: This cross-sectional study included 110 adult men without known cardiovascular, endocrine, oncological, or urological diseases evaluated at a hospital check-up clinic. Participants were grouped according to the presence of MetS. Erectile function (International Index of Erectile Function-5 [IIEF-5]), lower urinary tract symptoms (International Prostate Symptom Score [IPSS]), prostate volume, and internal iliac artery RI were assessed. Group comparisons were performed using non-parametric tests and the chi-square test, as appropriate.
Results: Participants with MetS had significantly lower IIEF-5 scores and a higher prevalence of erectile dysfunction compared with MetS and without MetS (P=0.042). Although IPSS scores and prostate volume tended to be higher in the MetS group, these differences were not statistically significant (P>0.05). No significant differences were observed in internal iliac artery RI values between groups (P>0.05).
Conclusions: MetS is significantly associated with erectile dysfunction and may contribute to impaired urogenital health. Internal iliac artery RI alone does not appear to be a sensitive early marker of urogenital vascular impairment.
Keywords
Metabolic Syndrome, Erectile Dysfunction, Prostate Volume, Internal Iliac Artery, International Prostate Symptom Score, International Index of Erectile Function-5
References

1. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48. doi: 10.1186/1741-7015-9-48.

2. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. doi: 10.1007/s11906-018-0812-z.

3. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl. 2009;30(1):10-22. doi: 10.2164/jandrol.108.005215.

4. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J Endocrinol Invest. 2011;34(7):557-567. doi: 10.3275/7806.

5. Vikram A, Jena G, Ramarao P. Insulin-resistance and benign prostatic hyperplasia: the connection. Eur J Pharmacol. 2010;641(2-3):75-81. doi: 10.1016/j.ejphar.2010.05.042.

6. Guay AT. ED2: erectile dysfunction = endothelial dysfunction. Endocrinol Metab Clin North Am. 2007;36(2):453-463. doi: 10.1016/j.ecl.2007.03.007.

7. Guay A, Jacobson J. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med. 2007;4(4 Pt 1):1046-1055. doi: 10.1111/j.1743-6109.2007.00530.x.

8. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 2012;10(1):4-18. doi: 10.2174/157016112798829760.

9. Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol. 1994;140(10):930-937. doi: 10.1093/oxfordjournals.aje.a117181.

10. Yannas D, Frizza F, Vignozzi L, Corona G, Maggi M, Rastrelli G. Erectile Dysfunction Is a Hallmark of Cardiovascular Disease: Unavoidable Matter of Fact or Opportunity to Improve Men's Health? J Clin Med. 2021;10(10):2221. doi: 10.3390/jcm10102221.

11. Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2015;115(1):24-31. doi: 10.1111/bju.12728.

12. Rastrelli G, Vignozzi L, Corona G, Maggi M. Testosterone and Benign Prostatic Hyperplasia. Sex Med Rev. 2019;7(2):259-271. doi: 10.1016/j.sxmr.2018.10.006.

13. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond). 2005;29(3):310-316. doi: 10.1038/sj.ijo.0802881.

14. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61(3):560-570. doi: 10.1016/j.eururo.2011.11.013.

15. Huang WL, Tung SY, Tseng CS, et al. The flow index provides a comprehensive assessment of erectile dysfunction by combining blood flow velocity and vascular diameter. Sci Rep. 2022;12(1):16099. doi: 10.1038/s41598-022-19364-5.

There are 15 references in total.
How to Cite
1.
Sönmez Topcu F, Özmerdiven G, Demirel HC. The Relationship Between Metabolic Syndrome and Urogenital Health Markers: A Cross-Sectional Study. Eur Res J. 2026;12(5):507-514. doi:10.18621/eurj.1780810
License
Creative Commons License

Copyright (c) 2026 The European Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

View Forthcoming Issue: Vol. 12 - Iss. 5 (May 2026)

Forthcoming Issue: Vol. 12 - Iss. 5 (May 2026)

Article Information

  • File Downloads 12
  • Abstract Views 40
  • Altmetrics
  • Share
Download data is not yet available.